The Spanish subsidiary of Leo Pharma closed 2024 with an increase in its turnover of 4%, to 96.9 million euros. The company’s forecasts for our country is keep on the growth path Also in this 2025, with the potential arrival to the Spanish market of various products.
This has been shown by Juan Fran Cuello de Oro, general director of Leo Pharma in Spain during an interview with the Spanish-Invertia. “I can’t give numbers, but we believe we will continue at the same level of growth that the one we have achieved in 2024, “he said.
The pharmaceutical company is currently in talks with the Ministry of Health to get price and financing of a medicine against chronic hand eccema. “We put it in the hands of the Ministry as soon as you get the approval of the European Medication Agency last year.” Could be available for patients This same year“But that doesn’t depend on us,” he detailed.
In addition, the company has a broad development strategy of pipeline. “We have internal development products and we have also reached strategic agreements with other companieslike Gilead the Debra “.
In collaboration with GileadLeo Pharma is developing a molecule for the possible treatment of patients with inflammatory diseases. “The agreement was signed four or five months ago and the objective is to jointly develop this therapy.”
The general director of Leo Pharma in Spain during the interview.
The second collaboration is with Debra. In this case, companies are developing a medicine to treat ampolly epidermolysis. This is a group of genetic diseases that cause fragility in the skin, causing blisters and sores easily.
Leo Pharma’s strategy is “being leaders in dermatology.” “We will continue looking for solutions for all dermatological diseases, but We do not rule out venturing in other areas“Golden Neck has continued.
Investments
Leo Pharma annually invests two million euros in Spain. Globally, the Danish pharmaceutical company invests 16% of its turnover in research and development of new medications.
“Spain is classified as a priority country for the company.” On the possibilities of opening a factory in our country, Cuello de Oro has explained that in the short term “the decision of a factory is complex, but in the long term we do not rule out any element of growth in Spain.”
The drug law
In Spain they are brewing different regulations that affect the pharmaceutical industry: the Royal Decree of Health Technologies, the Price and Financing and the Law of Medicines and Health Products.
Regarding the latter, the Council of Ministers approved the preliminary draft on April 8. A text that has been refused by laboratories mainly for the selected price system proposed by the Ministry of Health.
Alberto Ortega / Europa Press
“We are aligned with Farmaindustria’s position,” he said. “It is important that a new standard be reached that guarantees the Innovation and sector investment. Always from the dialogue, which is necessary at the moment. “
“We live an intense and collaboration moment. The goal is for innovation to reach patients, that the supply chain does not suffer and that the investment is ensured. “All this” with a stable regulatory framework, “he added.
Duty
The president of the United States, Donald Trump, has threatened to submit tariffs to the pharmaceutical industry. On this subject, Cuello de Oro has recognized that “we are in a complex geopolitical moment.”
“We have to be attentive and prepared for any element of change. In principle, tariffs do not affect medications for now, but our goal is to work with the authorities and our partners to guarantee the supply and that affect the least possible to production plants. “
